Here are five key notes:
1. The generic will cost half as much as EpiPen, carrying a list price of $300 for a two-pack.
2. In a statement, Mylan said the “unprecedented action” of launching the generic aims to increase patient access as well as present saving opportunities for payers.
3. Mylan came under fire earlier this year for its high EpiPen prices. Over 10 years, the drug’s price for a two-pack of auto-injectors increased from $100 to more than $600.
4. In September 2016, Mylan CEO Heather Bresch testified in front of Congress over EpiPen prices, saying the prices are due to the healthcare industry shifting prices onto consumers.
5. Mylan’s generic may be in direct competition with Petah Tikva, Israel-based Teva Pharmaceuticals, which is creating its own generic to EpiPen.
More articles on healthcare:
SCA builds upon Advocate Health Care partnership through 2 ASC deals; Nobilis Health voluntarily delists from Toronto Stock Exchange & more — 5 key notes
Surgery Partners receives ‘buy’ rating — 4 facts
UMBD Orthopaedics & Sports Medicine expands: 3 things to know
